NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Inovio Pharmaceuticals, Inc. INO
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$65,343
▼ 70.0% vs FY2024
EPS · FY25
$-1.81
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-183.5%
Net margin · FY25
-130000.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 65,343.00
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 130000 cents on every revenue dollar this year.
Per share
USD -1.81
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-183.5%
Return on equity, FY2025
ROE
Operating margin-132871.3%
Net margin-130000.0%
Return on assets-90.6%
Each USD of equity lost 183 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−61.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−81.5%
−61.2%
−47.4%
−26.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years+66.9%
Change, 10 years—
The share count grew 67% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 74.3M
total assets, end of FY2025
Total assetsUSD 74.3M
EquityUSD 24.1M
CashUSD 44.3M
Current ratio1.40×
Equity funds 32% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
−0.3
−0.3
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.1
−0.1
−0.3
−0.3
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.1
−0.1
−0.1
−0.3
−0.3
−0.2
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.81
−3.95
−6.09
−14.07
−17.45
−1.07
−1.21
−1.05
−1.09
−1.01
−0.44
−0.64
−1.43
−0.58
−0.12
−0.17
−0.33
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−183.5
−115.4
−79.5
−90.0
−70.6
−71.6
−264.2
−84.6
−66.4
−49.3
−20.3
−44.1
−152.1
−48.2
−32.5
−37.9
·
Shares out B
0.07
0.04
0.02
0.02
0.22
0.19
0.10
0.10
0.09
0.07
0.07
0.06
0.05
0.14
0.13
0.11
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed